E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic rhinosinusitis with nasal polyps and asthma |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10080060 |
E.1.2 | Term | Chronic rhinosinusitis with nasal polyps |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective is to show better disease control in patients with CRSwNP who have received both biologic treatment and surgery compared with patients who have received biologic treatment only at the 6-month follow-up. Another objective is to examine the differences in CRS control after 12 months, as indicated by SNOT22, between the two different treatments (biologic/surgery vs. biologics only) to examine the sustainability of combined treatment. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients ≥ 18 years old at the time of signed informed consent (no upper limit) • Patients who are referred to the outpatient clinic for the following reasons: o Doctor’s diagnosis of CRS • NPS ≥ 2+2 out of a score of 8 (max) • Severity measured as an SNOT22 score > 35 • One FESS surgery in general anaesthesia performed prior to inclusion (no time limitations) • No course of systemic steroids within the last 3 months, whereas a daily low dose is allowed • Possible doctor’s diagnosis of asthma
|
|
E.4 | Principal exclusion criteria |
• Patients who, because of language barriers, are not able to understand written information and, thus, are not able to answer questionnaires • Patients who currently receive biologics for any other disease • Patients who have previously or currently received biologics for CRS or asthma • Patients who are not able to give informed consent (i.e., patients who are permanently incapable) • Patients who meet ≥1 of the following: o Malignant lung disease o Cardiac disease of clinical importance o Current pregnancy and breastfeeding, as well as planning to be pregnant in the near future o Unwillingness to have FESS performed • Patients needing FESS or systemic steroids (OCS) during the study period will be excluded after an unscheduled visit (last observation carried forward (LOCF)) • Patients who are not eligible because of the investigator’s judgement
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
A significant change in HRQL using SNOT22 after a 6-month follow-up |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
To evaluate variables such as NPS, NCS, sense of smell, sleep, middle ear pressure, exacerbation, use of extra steroids, ACQ and inflammatory biomarkers in blood, sputum and polyp tissue, after 12 months, as well as SNOT22 and VAS differences will be examined in patients from both treatment arms, and the differences between the two treatments will be analysed. The need for surgical intervention or systemic steroids in the FESS group versus the non-FESS group between 6 and 12 months will be analysed. A change in adherence to the baseline treatment after 12 months of biologic drug treatment will be measured. A change in the CT scan of the sinuses after 12 months of biologic treatment (score based) using the Lund Mackay scale (0 to 24, higher = worse) compared with CT scan prior to treatment will be checked. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
No Sinus Surgery vs. sinus surgery |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |